Overview

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Status:
Unknown status

Trial end date:
2019-12-01

Target enrollment:

Participant gender:

Summary

The study aims to investigate the efficacy and safety of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI.

Phase:

Phase 3

Details

Lead Sponsor:

Shandong Cancer Hospital and Institute

Collaborator:

AstraZeneca

Treatments:

Osimertinib